One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
Home ➤ Press Releases ➤ Enable Injections and ARespo Biopharma Establish Strategic Partnership to Advance Biopharmaceutical Development
Enable Injections and ARespo Biopharma Establish Strategic Partnership to Advance Biopharmaceutical Development
Enable Injections and ARespo Biopharma Establish Strategic Partnership to Advance Biopharmaceutical Development
  • Home ➤ Press Releases ➤ Enable Injections and ARespo Biopharma Establish Strategic Partnership to Advance Biopharmaceutical Development

Enable Injections and ARespo Biopharma Establish Strategic Partnership to Advance Biopharmaceutical Development

enable injections logo

CINCINNATI and BOSTON, Nov. 19, 2026 — Enable Injections, Inc. (“Enable”), a healthcare innovation company specializing in the development and manufacturing of the enFuse® On-Body Delivery System, and ARespo Biopharma, Inc. (“ARespo”), a biotechnology company developing next-generation Alpha-1 Antitrypsin therapies, have announced a strategic partnership to integrate Enable’s enFuse technology into selected ARespo development programs.

ARespo is developing treatments to address ongoing unmet medical needs among individuals living with Alpha-1 Antitrypsin Deficiency (AATD). Its initial focus is on developing differentiated AATD replacement therapies designed to improve clinical outcomes and enhance the overall patient treatment experience.

“At ARespo, we are committed to advancing innovative treatments for Alpha-1 Antitrypsin Deficiency, where significant unmet patient needs remain,” said Jay Mohr, CEO and Co-founder of ARespo Biopharma. “Our partnership with Enable supports our vision of developing therapies that have the potential to improve outcomes while enhancing treatment convenience and quality of life for people living with AATD and their families. We look forward to leveraging Enable’s commercially-approved drug delivery technology as we advance our development programs.”

Scott Santarella, CEO of the Alpha-1 Foundation (A1F), a nonprofit organization dedicated to finding a cure for Alpha-1 Antitrypsin Deficiency and improving the lives of affected individuals worldwide, welcomed the collaboration. He noted that the organization supports innovative approaches that could provide new treatment options for patients.

Enable’s enFuse On-Body Injector is designed to administer large volumes of small-molecule and biologic medications through subcutaneous delivery. The technology provides an alternative to intravenous administration and supports treatment at home, offering patients greater flexibility in managing their care.

“Partnering with ARespo reflects our shared commitment to advancing innovation in drug delivery,” said Michael D. Hooven, Chairman and CEO of Enable Injections. “In rare diseases, where treatment options and the patient experience can present unique challenges, we see an opportunity to work alongside innovative biopharmaceutical companies like ARespo to advance therapies designed with patients in mind. We’re proud to support ARespo’s development programs with our enFuse technology and look forward to the potential impact this collaboration could have for patients and caregivers.”

The enFuse platform is designed to deliver medications through a simple, discreet, and comfortable administration experience. It also supports flexible treatment settings, including self-administration at home, potentially reducing the need for patients to visit healthcare facilities for treatment.

About ARespo Biopharma

ARespo Biopharma is a Boston-based biotechnology company focused on developing innovative therapies for Alpha-1 Antitrypsin Deficiency (AATD), a serious genetic condition associated with significant unmet medical needs. Its lead candidate, ABP-101, is a recombinant AAT-HSA fusion protein engineered for subcutaneous administration every two weeks, with the objective of improving treatment convenience and the patient experience.

Led by biotechnology executives with extensive experience in rare disease development and commercialization, ARespo aims to expand treatment options and improve the quality of life of individuals living with AATD and their families. For more information, visit arespobio.com.

About Enable Injections

Enable Injections is a Cincinnati-based global healthcare innovation company focused on improving the patient treatment experience through the development and manufacturing of its enFuse® On-Body Delivery System. The wearable drug delivery technology is designed to administer large volumes of pharmaceutical and biologic therapies through subcutaneous injection, with the aim of improving treatment convenience, supporting patient outcomes, and contributing to healthcare system efficiency.

Enable collaborates with pharmaceutical companies on clinical trials and the development of commercial launch plans for therapies combined with its enFuse technology. For additional information, visit enableinjections.com.

Media Contacts

ARespo Biopharma
Jay Mohr
Chief Executive Officer and Co-founder
[email protected]
(617) 645-1575
www.arespobio.com

Enable Injections
Jenn Beeson
[email protected]
(513) 607-0267
www.enableinjections.com

Related Press Releases

  • TestMu AI Integrates Postman Collections and OpenAPI Specifications into KaneAI for API Test Creation and Debugging
  • Walls.io Launches 24/7 AI Content Moderation Tool with Customizable Rules
  • Pinewood.AI Adds ChatGPT Advertising to Boost for Automotive Dealerships
  • Henderson Technology Acquires htec and Azpiral From PDI Technologies
  • TechnoVision: Top 5 Tech Trends to Watch in 2027 By Capgemini
  • AGC Biologics Welcomes Multiple Cell Therapy Projects at Its New Yokohama Facility
Latest report from the featured industries
  • Advanced Materials
    Optical Coating Market
    Spray Drying Equipment Market
    Metal Roofing Market
    Stone And Tile Adhesives And Sealants Market
    Armor Materials Market
    PTFE Hoses Market
    Roofing Materials Market
    Acrylic Foam Tape Market
    Oil Shale Market
    Pine-Derived Chemicals Market
  • Aerospace and Defence
    Satellite Launch Systems Market
    Satellite Communication In The Defense Sector Market
    Lyocell Fabric Market
    Bullet Proof Jacket Market
    Rescue Pole Market
    Police Baton Market
    Drone Battery Market
    Gunshot Detection System Market
    Military Electro-optical And Infrared Systems Market
    Multirotor Drone Market
  • Agriculture & Agri Products
    Mooring Systems Market
    Oilseed Processing Market
    Cut Flowers Market
    Cotton Processing Market
    Farm Equipment Rental Market
    Agricultural Variable Rate Technology Market
    Indoor Farming Technology Market
    Essential Oils And Plant Extract For Livestock Market
    Food Vacuum Machine Market
    Ornamental Horticulture Market
  • Apparel | Fashion & Accessories
    3D Printed Shoes Market
    3D Printed Jewelry Market
    Cotton (Linter) Pulp Market
    Snow Boots Market
    Merchandise Designing Market
    Volleyball Shoes Market
    Smart Clothing Market
    Workwear Market
    Down Jacket Market 
    Decorated Apparel Market
  • Artificial Intelligence
    AI-Based Defect Detection Software Market
    AI Vision For Manufacturing Market
    AI Training Data Lineage Software Market
    AI Portfolio And Pipeline Management Software Market
    AI In Testing Inspection And Certification Market
    Agentic AI Market
    AI In Telecommunication Market
    AI In Materials Science Market
    AI Data Labeling Market
    AI Data Center Power Consumption Market
✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • Our Clients
  • Media Mentions
  • Infographics
  • Statistics and Facts
  • Research Methodology
  • Why Choose Us?
Secured Payment Options
Secured Payment Options

© 2026 Market.Us. All Rights Reserved.